The rise in long-term HIV survivorship as a result of the introduction of effective antiretroviral therapy (ART) over the past decades has generated new awareness of the sequelae of both HIV infection and of the therapeutics used to treat HIV patients. Accumulating evidence of comorbidities associated with HIV infection and treatment with antiretroviral (ARV) drugs includes significant dyslipidemia and elevated risk of developing atherosclerotic cardiovascular disease (CVD). The goal of this project is to investigate a novel mechanism of ART-associated dyslipidemia and cardiovascular disease (CVD). Several ARV drugs have been identified as potent agonists for the pregnane X receptor (PXR), a nuclear receptor activated by numerous drugs, xenobiotic and dietary chemicals. PXR functions as a xenobiotic sensor that induces expression of genes required for xenobiotic metabolism in the liver and intestine. In the past decade, the function of PXR in the regulation of drug and xenobiotic metabolism has been extensively studied by many laboratories and the role of PXR as a xenobiotic sensor has been well established. We have recently revealed the pro-atherogenic effects of PXR in animal models and demonstrated that chronic PXR activation induces hyperlipidemia in wild-type mice and increases atherosclerosis in atherosclerosis-prone apolipoprotein E-deficient (ApoE-/-) mice. Preliminary studies demonstrated that HIV protease inhibitor amprenavir activates PXR and induces hyperlipidemia in wild- type mice but not in PXR-deficient mice; furthermore, follow-up study of currently used first-line ARV drugs subsequently found that these drugs activated PXR and induced PXR-mediated gene expression. The goal of this project is to generate novel mechanistic insights into ART-associated dyslipidemia and risk of CVD. Our central hypothesis is that long-term treatment with ARV drugs that activate PXR will lead to aberrant lipid homeostasis and accelerated atherosclerosis. We propose the following specific aims to test this hypothesis: 1) Determine the contribution of PXR towards the adverse effects of currently recommended ARV drugs on lipid homeostasis; 2) Define the molecular mechanisms through which PXR agonistic ARV drugs induce hyperlipidemia; and 3) Determine the impact of ARV drug-mediated PXR activation on macrophage functions and atherosclerosis development. These studies will provide critical mechanistic insights and new understandings of ART-associated dyslipidemia and CVD risk and will have direct clinical consequences for patients undergoing long-term treatment with PXR agonistic drugs.

Public Health Relevance

Infection with HIV is known to elevate the risk for serious heart and arterial disease. With the advent of new generations of drugs for HIV infection, the number of long-term HIV-infected patients has brought new recognitions of drug-related side effects, including altered lipid profiles and even more greatly increased risk for heart and arteril disease. This study will provide important new information about the impact of HIV therapy on cardiovascular disease in patients undergoing long-term treatment with these drugs.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL123358-03
Application #
9273599
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Fleg, Jerome L
Project Start
2015-08-01
Project End
2019-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
3
Fiscal Year
2017
Total Cost
$373,523
Indirect Cost
$123,523
Name
University of Kentucky
Department
Nutrition
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Sui, Yipeng; Liu, Zun; Park, Se-Hyung et al. (2018) IKK? is a ?-catenin kinase that regulates mesenchymal stem cell differentiation. JCI Insight 3:
Wang, Fang; Liu, Zun; Park, Se-Hyung et al. (2018) Myeloid ?-Catenin Deficiency Exacerbates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol 38:1468-1478
Memetimin, Hasiyet; Li, Dong; Tan, Kaiyuan et al. (2018) Myeloid Specific Deletion of Thrombospondin 1 Protects Against Inflammation and Insulin Resistance in Long-term Diet-induced Obese Male Mice. Am J Physiol Endocrinol Metab :
Sui, Yipeng; Park, Se-Hyung; Wang, Fang et al. (2018) Perinatal Bisphenol A Exposure Increases Atherosclerosis in Adult Male PXR-Humanized Mice. Endocrinology 159:1595-1608
Helsley, Robert N; Zhou, Changcheng (2017) Epigenetic impact of endocrine disrupting chemicals on lipid homeostasis and atherosclerosis: a pregnane X receptor-centric view. Environ Epigenet 3:
Zhou, Changcheng (2016) Novel functions of PXR in cardiometabolic disease. Biochim Biophys Acta 1859:1112-1120
Helsley, Robert N; Sui, Yipeng; Park, Se-Hyung et al. (2016) Targeting I?B kinase ? in Adipocyte Lineage Cells for Treatment of Obesity and Metabolic Dysfunctions. Stem Cells 34:1883-95
Park, Se-Hyung; Liu, Zun; Sui, Yipeng et al. (2016) IKK? Is Essential for Adipocyte Survival and Adaptive Adipose Remodeling in Obesity. Diabetes 65:1616-29
Cui, Wenpeng; Maimaitiyiming, Hasiyeti; Zhou, Qi et al. (2015) Interaction of thrombospondin1 and CD36 contributes to obesity-associated podocytopathy. Biochim Biophys Acta 1852:1323-33